Related Experiment Videos
The economic potential of dual individualisation methodologies
J A Paladino1, G S Zimmer, J J Schentag
1Clinical Pharmacokinetics Laboratory, Millard Fillmore Health System, University at Buffalo, New York, USA.
Pharmacoeconomics
|November 3, 1996
Summary
Dual individualisation optimizes antibacterial therapy by simultaneously considering patient drug levels and bacterial susceptibility. This cost-effective approach leads to faster infection cures and reduced healthcare costs.
Area of Science:
- Pharmacology
- Infectious Diseases
- Health Economics
Background:
- Rapid response to bacterial infections is crucial for cost-effective patient care and reduced healthcare resource utilization.
- Traditional antibacterial therapy may not always ensure optimal drug exposure and efficacy.
- Innovative strategies are needed to enhance the speed and effectiveness of antibacterial treatments.
Purpose of the Study:
- To introduce and evaluate the concept of dual individualisation for optimizing antibacterial therapy.
- To assess the cost-effectiveness of dual individualisation in treating bacterial infections.
- To demonstrate the practical implementation of dual individualisation in clinical settings.
Main Methods:
- Dual individualisation integrates pharmacokinetic (PK) and pharmacodynamic (PD) interactions.
- Key parameters include area under the curve (AUC) and minimum inhibitory concentration (MIC), forming the area under the inhibitory curve (AUIC) ratio.
- A computer model facilitates AUIC24h calculation, avoiding direct measurement of serum drug concentrations and bacterial MIC.
Main Results:
- Clinical studies with cephalosporins and fluoroquinolones demonstrated successful achievement of target AUIC24h values (125-250).
- Economic evaluations confirmed that dual individualisation is a cost-effective treatment strategy.
- The method is implementable in most clinical settings using existing data.
Conclusions:
- Dual individualisation represents an innovative and effective approach to optimizing antibacterial therapy.
- Achieving target AUIC values leads to significant economic benefits through improved treatment outcomes.
- This strategy enhances the rapid cure of bacterial infections, reducing healthcare costs.